FDA to Review New Long-Acting Generic Dexmethylphenidate (CTx-1301) for ADHD
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, with a PDUFA target date of May 31. The drug demonstrated rapid onset and sustained symptom relief lasting up to 12 hours in Phase 3 studies.
CTx-1301 and the End of Booster Doses: Why the FDA's May 31 Decision Reshapes the $23 Billion ADHD Market
The Bottom Line: What's Really Happening
On May 31, 2026, the FDA will decide on the NDA for CTx-1301—a new form of dexmethylphenidate from Cingulate Inc. (NASDAQ: CING). At first glance, it's just another stimulant in an oversaturated market. In reality, it's a technological answer to a problem long considered inevitable: the need for booster doses.
Over 60% of ADHD patients today use additional short-acting stimulants in the afternoon to extend the effect of their primary medication. This means a return of symptoms at school or work, the need to remember a second pill, the risk of stigmatization for children who must visit the school nurse, and potential for abuse of short-acting forms.
CTx-1301 solves this at the delivery level. The Precision Timed Release (PTR) platform is a single tablet with three precisely synchronized bursts of active drug. Pharmacokinetically, it's equivalent to taking three doses throughout the day, but with a single morning administration.
The FDA accepted the application under the 505(b)(2) pathway, meaning Cingulate doesn't need to prove the safety and efficacy of dexmethylphenidate from scratch—only that its delivery system creates a clinically meaningful difference from existing products. The company received a PDUFA fee waiver as a small business, saving $4.3 million.
Timeline and Context
The story unfolded methodically. In July 2023, Cingulate launched Phase 3 in a laboratory classroom study—the most rigorous design for evaluating the time profile of an ADHD stimulant, where children aged 6–12 are in a controlled environment for 15 consecutive hours and their behavior is assessed by trained observers. In April 2025, the company held a pre-NDA meeting with the FDA, confirming the adequacy of the clinical and CMC package. In October 2025, the application was accepted with a PDUFA date of May 31, 2026.
At AACAP 2025, lead investigator Ann Childress presented pediatric data: CTx-1301 showed dose-dependent improvement on the ADHD-RS-5 scale with large effect sizes, especially for the 37.5 mg dose. Crucially, the effect persisted into the evening hours—precisely when most current-generation extended-release products begin to lose activity.
Safety showed nothing unexpected: no serious adverse events in nine clinical studies, with a profile typical of methylphenidates—decreased appetite, mild insomnia—manageable through dose titration.
By the time of the NDA submission, Cingulate had already signed an exclusive commercial manufacturing contract with Bend Bio Sciences, appointed Brian Downey as Chief Commercial Officer, and engaged Indegene—a digital-first commercialization company—to build launch infrastructure.
Who Wins and Who Loses
Winners:
- Cingulate Inc. — If approved, the company transitions from development-stage to commercial-stage. With a current market cap of around $7–9 million and cash of about $6.1 million at the end of Q3 2025 plus $6 million in post-quarter financing, even a modest share of the ADHD market would transform its valuation. The global ADHD market exceeds $23 billion annually.
- Children and adolescents aged 6–17. One study showed CTx-1301 works throughout the active day without a booster dose. For a child, this means no visit to the school nurse, no stigmatization in front of classmates, no symptom "rebound" during fifth period.
- Parents. Adherence is a critical problem in pediatric ADHD. The more complex the dosing regimen, the lower the adherence. One pill in the morning versus two to three doses a day is the difference between controlled and uncontrolled symptoms for tens of thousands of families.
- Adult patients. Phase 3 in adults showed clinically meaningful improvements on AISRS and PERMP. Adults with ADHD are the fastest-growing market segment, and for them, evening symptom control is critical: helping children with homework, driving, working a second shift.
Losers:
- Manufacturers of short-acting stimulants for booster therapy. If CTx-1301 is approved and truly covers the entire active day, the need for IR boosters for a significant portion of patients disappears. This is a market segment that exists solely due to the imperfections of current extended-release forms.
- Concerta and its generics. The original OROS-methylphenidate was once a revolution—a 12-hour profile. But its kinetics have a "dip" in the early evening hours. If CTx-1301's evening control data are confirmed in real-world practice, this will become a reason for switching.
- Manufacturers of non-stimulant ADHD therapies. Atomoxetine (Strattera), guanfacine ER (Intuniv) occupy the "stimulant alternative" niche. But if a stimulant with an ideal "one pill, all day" profile appears, some patients who chose non-stimulants due to inconvenient dosing regimens may reconsider.
What the Media Isn't Saying
The key non-obvious insight: CTx-1301 is not so much a drug as a demonstration of the PTR platform as an asset. Cingulate is already developing CTx-1302 (dextroamphetamine on the same platform) and CTx-2103 for anxiety. If the FDA approves CTx-1301, it validates PTR as a universal delivery system applicable to different molecules and therapeutic areas. For the market, this means Cingulate is not a one-product company but a platform biotech firm whose value should be assessed as the sum of its pipeline.
Second point—the 505(b)(2) pathway. Most commentators mention it as a technical detail. But it's a strategic choice. 505(b)(2) allows Cingulate to reference existing data on dexmethylphenidate (Focalin, Focalin XR), avoiding a full NDA cycle. This saved the company years and tens of millions of dollars. More importantly, it sets a precedent for other small-cap biotechs: you can innovate in delivery without inventing a new molecule, and the FDA is open to that.
Third insight—Cingulate's economics. The company received a PDUFA fee waiver—$4.3 million in savings. For a biotech with $6.1 million cash on hand, this is the difference between life and death. Cingulate also signed a commercial manufacturing contract with Bend Bio Sciences before approval. This is a risky move—production capacity is reserved for a product not yet approved—but it also enables immediate launch on approval day, without a 6–12 month scale-up delay.
Fourth point—silence on price. Cingulate has not disclosed the planned price for CTx-1301. This is no accident. Dexmethylphenidate is a mature molecule; generics of Focalin XR are already on the market. If Cingulate prices above generics, payers will demand step therapy. If priced at generic levels, margins will be thin. The likely strategy: price between generics and branded extended-release products (Vyvanse, Concerta), with a focus on pharmacoeconomic arguments—"one pill instead of two reduces overall therapy costs by improving adherence and reducing doctor visits."
Forecast: Next 30 Days and 90 Days
30 days (through June 9, 2026):
- May 31, 2026—PDUFA date. Probability of approval: above 70%. Rationale: FDA accepted the application without requesting additional clinical studies; safety profile is clean and class-consistent; efficacy demonstrated in both adults and children; pre-NDA meeting confirmed package adequacy. No signals of approvability issues have emerged.
- If approved: CING shares will rise from current levels ($0.20–0.30) to $1.50–2.50 within the first week of trading—the market prices in binary risk, and a favorable resolution will trigger a sharp revaluation.
- Cingulate activates commercial launch: Indegene begins outreach to prescribing physicians; Bend Bio Sciences ships the first commercial batch.
- In case of a Complete Response Letter (CRL): shares fall below $0.10; the company will need emergency financing to continue operations.
90 days (through August 7, 2026):
- If CTx-1301 is approved: the drug will appear in U.S. retail pharmacies 4–6 weeks after approval—roughly the second half of July 2026. Cingulate hasn't disclosed the price, but analysts expect a range of $250–350 per monthly course.
- The first prescriptions will be written within a week of pharmacy availability. Early adopters are expected to be psychiatrists familiar with clinical trial data and parents of children currently experiencing "evening crash" on existing medications.
- Cingulate will likely announce progress on CTx-1302 (dextroamphetamine)—the second candidate on the PTR platform. If CTx-1301 is approved, the value of CTx-1302 automatically increases.
- Competitors—especially manufacturers of booster IR stimulants—will begin losing prescription share, though the effect will be gradual, not immediate: physicians are conservative, and it will take 6–12 months for real-world practice to shift.
- Insurers will start reviewing formularies. If Cingulate offers a price comparable to Focalin XR generics, payers may place CTx-1301 in a preferred tier, accelerating adoption.
Fundamental takeaway: May 31, 2026, is not just a decision date for another ADHD stimulant. It's the moment when delivery technology could change the standard of care. A century ago, doctors learned to treat ADHD with stimulants. Twenty years ago, extended-release forms emerged, freeing patients from taking pills every four hours. Now CTx-1301 promises to eliminate the last vestige of the old era—the booster dose. If the FDA says "yes," it will mean the regulator has recognized that "full active day" is not a marketing slogan but a measurable clinical endpoint achievable with a single pill.
— Editorial Team
